J.P. Morgan analyst Robbie Marcus has maintained their bullish stance on BSX stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robbie Marcus has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong growth potential and strategic positioning in the MedTech sector. The company is expected to achieve a compound annual growth rate (CAGR) of over 10% in organic sales from 2026 to 2028, driven by a robust pipeline of innovations and strategic mergers and acquisitions. This growth trajectory positions Boston Scientific as a leader in the large-cap MedTech space, with significant market expansion opportunities, particularly in international markets like China where a mid-teens sales CAGR is anticipated.
Additionally, Boston Scientific’s focus on improving its operating margins, with an expected annual expansion of 50 basis points, supports leveraged earnings growth. The company plans to maintain a strong free cash flow conversion rate of 70-80% over the long-range plan, enabling substantial capital deployment for value creation. The strategic emphasis on tuck-in acquisitions, alongside a broad and deep product pipeline, further solidifies Boston Scientific’s competitive advantage and potential for sustained growth, justifying the Buy rating by Robbie Marcus.
Marcus covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and Insulet. According to TipRanks, Marcus has an average return of 8.1% and a 51.98% success rate on recommended stocks.
In another report released today, Needham also reiterated a Buy rating on the stock with a $121.00 price target.